AlzeCure appoints Cecilia Wadell as new Head of Development
Cecilia Wadell
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, has appointed Cecilia Wadell, MScPharm, Ph.D., as Head of Development. She will be part of AlzeCure's management team. Her predecessor, Dr. Märta Segerdahl, will continue to focus on her role as CMO of AlzeCure.
Cecilia Wadell will take up her position as Head of Development on August 20 and will lead the clinical development organization in her role. Cecilia Wadell has more than 25 years of industry experience with senior positions at both major pharmaceutical companies and smaller biotech companies, e.g. AstraZeneca, Wilson Therapeutics, Medivir and World Wide Clinical Trials.
”I look forward to the strengthening of our development organization that Cecilia's appointment will bring. Cecilia has extensive experience in all phases of drug development and many years of experience in leadership roles,” said Märta Segerdahl, CMO.
”We are very pleased to have Cecilia join the team. Her extensive experience in running clinical development projects, including orphan drug projects, and building R&D organizations, will strengthen our clinical capacity as we now have several projects in or on their way to clinical development. Her experience from both large pharmaceutical companies and smaller biotech companies, as well as from the CRO side, will also be of great importance for the development work with our clinical projects, business development work and partnership discussions,” said Martin Jönsson, CEO of AlzeCure.
”I am excited to join AlzeCure at such an exciting time in the company's development. I hope to use my many years of clinical experience in clinical drug development to take AlzeCure's drug candidates to the next level,” said Cecilia Wadell.